Albireo Announces U.S. FDA Acceptance of New Drug Application for Odevixibat
BOSTON, Jan. 25, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage rare liver disease company developing novel bile acid modulators, today announced that the U.S. Food and Drug...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news
More News: Bile | Drugs & Pharmacology | Liver | Liver Disease | New Drug Applications | Pharmaceuticals | Urology & Nephrology